Bavarian Nordic has initiated two Phase III clinical trials of its mpox vaccine, Jynneos, in pregnant and breastfeeding women ...

Bavarian Nordic initiates clinical trials of mpox vaccine in infants and pregnant women: Copenhagen, Denmark Saturday, June 28, 2025, 12:00 Hrs [IST] Bavarian Nordic A/S, a global ...

Clinical trials of Jynneos have begun or will begin soon in infants and children 2 years old and younger, and in pregnant or ...

The FDA approval of Vimkunya has given the chikungunya vaccine’s owner, Bavarian Nordic, an extra financial windfall. | The ...

Sale prices for the vouchers – which slash FDA review times for a drug – have increased in the past year as biotech funding ...

View the latest Bavarian Nordic A/S ADR (BVNRY) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Bavarian Nordic produces one of the only vaccines for mpox and its shots are the only ones licensed for the disease in the U.S. and European Union.

Danish biotech firm Bavarian Nordic could ramp up production of its mpox vaccine even before having orders lined up, based on the outcome of talks this week with the World Health Organisation, the ...

Danish biotech firm Bavarian Nordic said on Tuesday it will donate 40,000 doses of its mpox vaccine to Africa's top public health body, after the body declared an emergency.

Bavarian Nordic is also sponsoring a trial (NCT06549530) of MVA-BN in children aged 2-11 years, with topline data anticipated in Q3 2025. Jynneos is the only non-replicating mpox vaccine approved ...

First studies to evaluate MVA-BN in infants under 2 years of age and pregnant and breastfeeding women.The multi-partner ...

First studies to evaluate MVA-BN in infants under 2 years of age and pregnant and breastfeeding women.The multi-partner research project is aimed at expanding access to mpox vaccines for vulnerable ...